Arm 2 cemiplimab and fianlimab

WITHDRAWN · PHASE1 · Hepatocellular Carcinoma

The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.